The angiotensin II type 1 receptor blocker valsartan in the battle against COVID‐19

OBJECTIVE: Severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) uses the host’s angiotensin‐converting enzyme 2 (ACE2) as a cellular entry point. Therefore, modulating ACE2 might impact SARS‐CoV‐2 viral replication, shedding, and coronavirus disease 2019 (COVID‐19) severity. Here, it was inv...

Descripción completa

Detalles Bibliográficos
Autores principales: de Ligt, Marlies, Hesselink, Matthijs K. C., Jorgensen, Johanna, Jocken, Johan W. E., Blaak, Ellen E., Goossens, Gijs H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
BRIEF CUTTING EDGE REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242711/
https://www.ncbi.nlm.nih.gov/pubmed/33955183
http://dx.doi.org/10.1002/oby.23221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242711/
https://www.ncbi.nlm.nih.gov/pubmed/33955183
http://dx.doi.org/10.1002/oby.23221

Ejemplares similares